Symposium report download
Download a written report of the symposium, published in the journal US Neurology
Professor Poewe has received honoraria for CME, consultancy services, research grants, and/or promotional speaking on behalf of: AbbVie, AstraZeneca, Bial, Biogen, Biohaven, Britannia, Grüenthal, Intec, Ipsen, Lundbeck, Novartis, NeuroDerm, Orion Pharma, Oxford Biomedica, Prexton, Regenera, Roche, Sunovion Pharmaceuticals Inc., Sun Pharma, Takeda, Teva, UCB, and Zambon.
Prof. Poewe is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Poewe.
Professor Poewe discusses the phenomenology and clinical significance of ‘OFF’ episodes, the motor and non-motor symptoms, when they occur, their incidence, the development of dyskinesias and underlying mechanisms.
Professor Olanow owns shares in Clintrex which provides consulting services to many companies developing products in the Parkinson’s disease space. Clintrex specifically provides consulting services for Sunovion Pharmaceuticals Inc.
Prof. Olanow is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Olanow.
Professor Olanow discusses the pathophysiology of ‘OFF’ episodes and associated risk factors. He highlights study findings showing the association of long-term high-dose levodopa exposure with ‘OFF’ episode development and approaches for reducing this risk.
Professor Rascol has received honoraria for consultancy services, scientific advisory boards, research grants, and/or promotional speaking on behalf of: AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, AstraZeneca, Bial, Biogen, Britannia, Clevexel, INC Research, Lundbeck, Merck, MundiPharma, Neuroderm, Novartis, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Sunovion Pharmaceuticals Inc., Teva, UCB, XenoPort, and Zambon.
Prof. Rascol is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Rascol.
Professor Rascol gives an overview of the current treatments of ‘OFF’ episodes in Parkinson’s disease. He stresses that ‘OFF’ episodes are a major unmet need in Parkinson’s disease and that faster-acting and longer-lasting therapies are vital in addressing this need.
Professor Stocchi has received honoraria for consultancy services, scientific advisory boards, research grants, and/or promotional speaking on behalf of: Chiesi Farmaceutici, EMD Serono, GlaxoSmithKline, Impax Laboratories, Lundbeck, Novartis, Merck Sharpe & Dohme, UCB, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
Prof. Stocchi is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Stocchi.
Professor Stocchi discusses new and investigational therapies for acute treatment of ‘OFF’ episodes. He emphasizes that these episodes are often the result of delayed delivery of levodopa to the jejunum and that alternative routes of delivery and alternate agents can reduce these issues.
Professor Poewe has received honoraria for CME, consultancy services, research grants, and/or promotional speaking on behalf of: AbbVie, AstraZeneca, Bial, Biogen, Biohaven, Britannia, Grüenthal, Intec, Ipsen, Lundbeck, Novartis, NeuroDerm, Orion Pharma, Oxford Biomedica, Prexton, Regenera, Roche, Sunovion Pharmaceuticals Inc., Sun Pharma, Takeda, Teva, UCB, and Zambon.
Prof. Poewe is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Poewe.
Professor Poewe discusses the phenomenology and clinical significance of ‘OFF’ episodes, the motor and non-motor symptoms, when they occur, their incidence, the development of dyskinesias and underlying mechanisms.
Professor Olanow owns shares in Clintrex which provides consulting services to many companies developing products in the Parkinson’s disease space. Clintrex specifically provides consulting services for Sunovion Pharmaceuticals Inc.
Prof. Olanow is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Olanow.
Professor Olanow discusses the pathophysiology of ‘OFF’ episodes and associated risk factors. He highlights study findings showing the association of long-term high-dose levodopa exposure with ‘OFF’ episode development and approaches for reducing this risk.
Professor Rascol has received honoraria for consultancy services, scientific advisory boards, research grants, and/or promotional speaking on behalf of: AbbVie, Adamas, Acorda, Addex, AlzProtect, Apopharma, AstraZeneca, Bial, Biogen, Britannia, Clevexel, INC Research, Lundbeck, Merck, MundiPharma, Neuroderm, Novartis, Oxford Biomedica, Parexel, Pfizer, Prexton Therapeutics, Quintiles, Sanofi, Servier, Sunovion Pharmaceuticals Inc., Teva, UCB, XenoPort, and Zambon.
Prof. Rascol is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Rascol.
Professor Rascol gives an overview of the current treatments of ‘OFF’ episodes in Parkinson’s disease. He stresses that ‘OFF’ episodes are a major unmet need in Parkinson’s disease and that faster-acting and longer-lasting therapies are vital in addressing this need.
Professor Stocchi has received honoraria for consultancy services, scientific advisory boards, research grants, and/or promotional speaking on behalf of: Chiesi Farmaceutici, EMD Serono, GlaxoSmithKline, Impax Laboratories, Lundbeck, Novartis, Merck Sharpe & Dohme, UCB, Sunovion Pharmaceuticals Inc., and Teva Pharmaceutical Industries Ltd.
Prof. Stocchi is a paid consultant for and presented at the satellite symposium on behalf of Sunovion Pharmaceuticals Inc. The views and opinions expressed are those of Prof. Stocchi.
Professor Stocchi discusses new and investigational therapies for acute treatment of ‘OFF’ episodes. He emphasizes that these episodes are often the result of delayed delivery of levodopa to the jejunum and that alternative routes of delivery and alternate agents can reduce these issues.
Four Parkinson’s disease experts discuss the phenomenology of ‘OFF’ episodes, associated risk factors and current treatment approaches.
These touchSYMPOSIUM HIGHLIGHTS videos were recorded live in March 2019.